Literature DB >> 19944887

Management of schizophrenia with obsessive-compulsive features.

Michael Y Hwang1, Sung-Wan Kim, Sun Young Yum, Lewis A Opler.   

Abstract

Although obsessive-compulsive symptoms (OCS) in schizophrenia have been conceptually controversial and clinically challenging, recent evidence suggests that schizophrenia with OCS may constitute a distinct schizophrenic subgroup. Recent epidemiological and clinical findings have shown that the subgroup obsessive-compulsive (OC) schizophrenia is associated with poor outcome and is more frequent than previously realized. Emerging biological evidence suggests that OCS in schizophrenia has more than one pathogenesis, with distinct mechanisms that may require different treatment interventions. Therefore, the management of OCS in patients with schizophrenia requires an individualized treatment approach based on the pathogenesis and clinical status of the patient. For example, the atypical antipsychotics that are potent serotonin antagonists sometimes induce de novo or exacerbate preexisting OCS, which resolves if the patient is switched to an antipsychotic with a different profile or if adjunctive treatment with serotonin reuptake inhibitors (SSRIs) is undergone. Regarding OC schizophrenia, SSRIs are often a necessary part of treatment, with knowledge of potential pharmacokinetic interactions with antipsychotic drugs essential. In this article, recent progress and current knowledge of OC schizophrenia is reviewed and treatment guidelines are offered for this complex and challenging subgroup of schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19944887     DOI: 10.1016/j.psc.2009.08.002

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  11 in total

1.  Comorbidity in Schizophrenia: Conceptual Issues and Clinical Management.

Authors:  Hussain Muhammad Abdullah; Hameed Azeb Shahul; Michael Y Hwang; Stephen Ferrando
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

2.  Suicidal obsessions as dose dependent side-effect of clozapine.

Authors:  Branka Aukst-Margetić; Branimir Margetić; Vlatka Boricević Marsanić
Journal:  Psychopharmacol Bull       Date:  2011

3.  The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders.

Authors:  Lieuwe de Haan; Bouke Sterk; Luuk Wouters; Don H Linszen
Journal:  Schizophr Bull       Date:  2011-07-28       Impact factor: 9.306

Review 4.  [Obsessive-compulsive symptoms in psychotic disorders: pathogenesis and treatment].

Authors:  Frederike Schirmbeck; Mathias Zink
Journal:  Nervenarzt       Date:  2022-07-05       Impact factor: 1.297

5.  Stable cognitive deficits in schizophrenia patients with comorbid obsessive-compulsive symptoms: a 12-month longitudinal study.

Authors:  Frederike Schirmbeck; Franziska Rausch; Susanne Englisch; Sarah Eifler; Christine Esslinger; Andreas Meyer-Lindenberg; Mathias Zink
Journal:  Schizophr Bull       Date:  2012-10-27       Impact factor: 9.306

6.  Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review.

Authors:  Frederike Schirmbeck; Mathias Zink
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

7.  Comorbidity of Obsessive-Compulsive Disorder and Schizophrenia in an Adolescent.

Authors:  Ahmad Nabil Md Rosli; Wan Salwina Wan Ismail
Journal:  Case Rep Psychiatry       Date:  2015-09-21

8.  Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors.

Authors:  Frederike Schirmbeck; Mathias Zink
Journal:  Front Pharmacol       Date:  2013-08-09       Impact factor: 5.810

9.  Prevalence and clinical characteristics of patients with obsessive-compulsive disorder in first-episode psychosis.

Authors:  Kristen Hagen; Bjarne Hansen; Inge Joa; Tor Ketil Larsen
Journal:  BMC Psychiatry       Date:  2013-05-30       Impact factor: 3.630

Review 10.  Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment.

Authors:  Mathias Zink
Journal:  Adv Med       Date:  2014-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.